Edition:
United States

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.78USD
3:59pm EST
Change (% chg)

$0.01 (+0.27%)
Prev Close
$3.77
Open
$3.80
Day's High
$3.92
Day's Low
$3.75
Volume
232,879
Avg. Vol
435,570
52-wk High
$4.71
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib
Thursday, 4 Jan 2018 07:30am EST 

Jan 4 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​.RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA.  Full Article

Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017
Friday, 15 Dec 2017 07:30am EST 

Dec 15 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017.COMPANY HAS INITIATED AN EXTERNAL SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.NELSON CABATUAN, RIGEL'S VICE PRESIDENT, FINANCE WILL SERVE AS COMPANY'S INTERIM PRINCIPAL ACCOUNTING OFFICER.  Full Article

Rigel announces Q3 loss of $0.14 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces third quarter 2017 financial results and provides company update.Q3 loss per share $0.14.  Full Article

Rigel announces proposed public offering of common stock
Tuesday, 3 Oct 2017 04:01pm EDT 

Oct 3 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces proposed public offering of common stock.Rigel Pharmaceuticals Inc - intends to offer and sell up to $40 million of shares of its common stock in an underwritten public offering.Rigel Pharmaceuticals Inc - proceeds to be used to fund research and development activities, commercial preparation.  Full Article

Rigel Q2 loss per share $0.16
Tuesday, 1 Aug 2017 04:01pm EDT 

Aug 1 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces second quarter 2017 financial results and provides company update.Q2 loss per share $0.16.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Aclaris Therapeutics completes phase 1 clinical trial of ati-50001
Friday, 5 May 2017 08:00am EDT 

May 5 (Reuters) - Aclaris Therapeutics Inc : :Aclaris Therapeutics completes phase 1 clinical trial of ati-50001 for the treatment of alopecia universalis and alopecia totalis.In trial, treatment with ati-50001 capsules was well tolerated, with a safety profile similar to placebo.No clinically significant laboratory abnormalities were observed.Aclaris Therapeutics - data consistent with results from earlier phase 1 clinical trial conducted by rigel pharma in which study drug was well tolerated at all doses.Aclaris Therapeutics - plans to initiate phase 2 dose ranging trial with ati-50001 for treatment of alopecia totalis, alopecia universalis in second half of 2017.Aclaris Therapeutics - plans to submit an investigational new drug application (ind) for ati-50002 for treatment of patchy alopecia areata in mid-2017.Plans to initiate phase 2 trial of ati-50002 for treatment of vitiligo in second half of 2017.Aclaris Therapeutics Inc - plans to initiate a phase 2 dose ranging trial of ati-50002 for treatment of patchy alopecia areata in second half of 2017.  Full Article

Rigel announces Q1 loss per share $0.13
Tuesday, 2 May 2017 04:01pm EDT 

May 2 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces first quarter 2017 financial results and provides company update.Q1 loss per share $0.13.Q1 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Rigel Pharmaceuticals Inc - As of March 31, 2017, Rigel had cash, cash equivalents and short-term investments of $98.1 million.Rigel Pharmaceuticals-Expects cash, cash equivalents and short-term investments to be sufficient to support current and projected funding requirements.Rigel Pharmaceuticals - Is selecting a molecule from its irak program for preclinical development.Rigel Pharmaceuticals-Expected that irak program development will include clinical evaluation in immunology areas, such as for lupus, gout and/or psoriasis.Rigel Pharmaceuticals Inc qtrly contract revenues from collaborations $3.6 million versus $5.0 million.  Full Article

Rigel submits NDA to FDA for fostamatinib in chronic itp
Monday, 17 Apr 2017 04:05pm EDT 

April 17 (Reuters) - Rigel Pharmaceuticals Inc ::Rigel submits new drug application to fda for fostamatinib in chronic itp.Rigel Pharmaceuticals Inc- company expects to receive notification regarding acceptance of NDA by FDA in June 2017.  Full Article

Rigel Q4 loss per share $0.16
Tuesday, 7 Mar 2017 04:01pm EST 

Rigel Pharmaceuticals Inc : Rigel announces fourth quarter 2016 and year end 2016 financial results and provides company update . Q4 loss per share $0.16 .Q4 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Great Point Partners LLC reports 7.47 pct passive stake in Rigel Pharmaceuticals Inc
Friday, 10 Feb 2017 12:58pm EST 

Rigel Pharmaceuticals Inc :Great Point Partners LLC reports 7.47 passive stake in Rigel Pharmaceuticals Inc as on January 31, 2017 - SEC filing.  Full Article

BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib

* RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​